Please assess the completion status of the following clinical trial:

Trial Title: Effects of Colesevelam HCl On Bile Acid Kinetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have given written informed consent~* BMI 25-35 kg/m\^2, inclusive~* Normal liver and thyroid function~* No history of liver, biliary, or intestinal disease~Diabetic Subjects~* Diagnosed Type 2 Diabetes Mellitus~* HbA1C = 6.7-10%~Normal Subjects~* 2 hr OGTT glucose \< 140 mg/dL~* fasting glucose \< 100 mg/dL~* TG \< 150 mg/dL~* HDL cholesterol \>= 40 mg/dL~Impaired Glucose Tolerance Subjects~* 2 hr OGTT glucose \>= 140 and \< 200 mg/dL~Exclusion Criteria:~* T1DM or history of diabetic ketoacidosis~* treatment with blood pressure lowering therapy that has not been stable for three months before screening~* colesevelam HCl, cholestyramine, or colestipol treatment for hyperlipidemia within the last three months~* treatment with thiazolidinedione (TZD) at any time~* treatment with insulin within past 6 months~* treatment with antibiotics within last 3 months~* extreme sportsmen~* treatment with medication affecting liver or intestinal function within the last 3 months~* allergic or toxic rxn to colesevelam HCl~* history of dysphagia, swallowing disorders, or intestinal motility disorder~* Serum Triglycerides \> 500 mg/dL at visit 1~* Serum LDL-C \< 60 mg/dL at visit 1~* any condition or therapy investigator believes not in subjects best interest~* use of any investigational drug within 30 days before screening~* chronic treatment with oral corticosteroids at any time or acute treatment within last three months~* hyperthyroidism or treatment with thyroid hormone/levothyroxine

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Normal Glucose Metabolism (Type: None): Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
- Impaired Glucose Tolerance (Type: None): Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
- Frank type 2 diabetes (Type: None): Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl

Based on this trial design, predict the completion outcome and termination type (if applicable).